Intravenous immunoglobulins as a treatment for alzheimers disease: Rationale and current evidence

Drugs

Volumn 70, Issue 5, 2010, Pages 513-528

  Dodel, Richard ^a   Neff, Frauke ^a   Noelker, Carmen ^a   Pul, Refik ^b   Du, Yansheng ^c   Bacher, Michael ^a   Oertel, Wolfgang ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACC 001; AMYLOID BETA PROTEIN; AUTOANTIBODY; BAPINEUZUMAB; CAD 106; GSK 933776A; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LY 2062430; NOOTROPIC AGENT; PF 04360365; PF 4360365; PIRACETAM; PLACEBO; PRION PROTEIN; QS 21; R 1450; SOLENAZUMAB; UNCLASSIFIED DRUG; V 950;

ABDOMINAL PAIN; ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANAPHYLAXIS; ARTHRALGIA; ARTHRITIS; ASEPTIC MENINGITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BACKACHE; CENTRAL RETINA ARTERY OCCLUSION; CHEST TIGHTNESS; CHILL; CLINICAL TRIAL; CONFUSION; DEEP VEIN THROMBOSIS; DEGENERATIVE DISEASE; DIAPHORESIS; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ENZYME DEFECT; EPIDERMOLYSIS BULLOSA; ERYTHEMA; ERYTHEMA MULTIFORME; FATIGUE; FEVER; FLUSHING; HAIR LOSS; HEADACHE; HEART PALPITATION; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; IMMUNOTHERAPY; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LICHENOID ERUPTION; LUNG EDEMA; LUNG EMBOLISM; MACULOPAPULAR RASH; MENINGOENCEPHALITIS; MOUTH ULCER; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PASSIVE IMMUNIZATION; PETECHIA; PRURITUS; PSEUDOHYPONATREMIA; REFRACTORY EPI; REVIEW; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; URTICARIA; UVEITIS; VOMITING;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; COGNITION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NERVE DEGENERATION; TREATMENT OUTCOME;

ANIMALIA;

EID: 77949962484     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11533070-000000000-00000     Document Type: Review

References (116)

1. Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006; 253 Suppl. 5: V18-24
2. Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3 (1): 36-44
3. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008; 15 (9): 893-908
4. Neff F, Wei X, Nolker C, et al. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008; 7 (6): 501-507
5. Mandelkow E, von Bergen M, Biernat J, et al. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 2007; 17 (1): 83-90
6. HardyJ. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 2006; 3 (1): 71-73
7. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007; 69 (16): 1622-1634
8. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008; 31: 175-193
9. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400 (6740): 173-177
10. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408 (6815): 982-985
11. Roskam S, Neff F, Schwarting R, et al. APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks. Neurosci Biobehav Rev 2010; 34 (4): 487-499
12. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64 (1): 94-101
13. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3 (10): 824-828
14. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64 (9): 1553-1562
15. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372 (9634): 216-223
16. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38 (4): 547-554
17. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6 (8): 916-919
18. Das P, Howard V, Loosbrock N, et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/-knock-out mice. J Neurosci 2003; 23 (24): 8532-8538
19. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9 (4): 448-452
20. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immuno-therapy. Nat Med 2001; 7 (3): 369-372
21. Taguchi H, Planque S, Nishiyama Y, et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 2008; 283 (8): 4714-4722
22. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98 (15): 8850-8855
23. Frenkel D, Maron R, Burt DS, et al. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005; 115 (9): 2423-2433
24. Solomon B. Antibody-mediated immunotherapy for Alzheimer's disease. Curr Opin Investig Drugs 2007; 8 (7): 519-524
25. Morgan C, Colombres M, Nunez MT, et al. Structure and function of amyloid in Alzheimer's disease. Prog Neuro-biol 2004; 74 (6): 323-349
26. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14 (8): 837-842
27. Sarsoza F, Saing T, Kayed R, et al. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol 2009; 118 (4): 505-517
28. Moretto N, Bolchi A, Rivetti C, et al. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epi-tope peptide. J Biol Chem 2007; 282 (15): 11436-11445
29. Petkova AT, Ishii Y, Balbach JJ, et al. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002; 99 (26): 16742-16747
30. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298 (5597): 1379
31. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002; 5 (5): 452-457
32. O'Nuallain B, Acero L, Williams AD, et al. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 2008; 47 (47): 12254-12256
33. Mohajeri MH, Gaugler MN, Martinez J, et al. Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo. Neurodegener Dis 2004; 1 (4-5): 160-167
34. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004; 24 (27): 6144-6151
35. Kountouris D. Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type. J Neural Transm 2000; 107 (5): 18
36. Dodel R, Du Y, Depboylu C, et al. Intravenous Immuno-globulins containing antibodies against b-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1472-1474
37. Relkin NR, Szabo P, Adamiak B, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30 (11): 1328-1336
38. Relkin N, Tsakanikas DI, Adamiak B, et al. A double blind, placebo-controlled, phase II clinical trial of intravenous immunoglobulin (IVIG) for treatment of Alzheimer's disease [abstract]. Neurology 2008; 70 (11): A393
39. A phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV 10%) for the treatment of mild to moderate Alzheimer's disease [Clinical-Trials.gov identifier NCT00818662]. US National Institutes of Health, ClinicalTrials.gov, 2009 [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2010 Feb 10]
40. Study of Octagam 10% on the treatment of mild to moderate Alzheimer's patients [ClinicalTrials.gov identifier NCT00812565]. US National Institutes of Health, Clin-icalTrials.gov, 2009 [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Feb 10]
41. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001; 57 (5): 801-805
42. Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002; 52 (2): 253-256
43. Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002; 37 (7): 943-948
44. Shoenfeld Y, Gershwin ME, Meroni PL. Autoantibodies. Amsterdam: Elsevier, 2007
45. Fillit H, Hess G, Hill J, et al. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009; 73 (3): 180-185
46. Misra N, Bayry J, Ephrem A, et al. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 2005; 252 Suppl. 1: I1-6
47. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255 Suppl. 3: 3-6
48. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345 (10): 747-755
49. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-533
50. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8 (1): 34-47
51. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-290
52. Bruhns P, Samuelsson A, Pollard JW, et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18 (4): 573-581
53. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291 (5503): 484-486
54. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98 (4): 1095-1099
55. Siragam V, Crow AR, Brinc D, et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12 (6): 688-692
56. Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human im-munoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 2006; 135 (1): 97-100
57. Akilesh S, Petkova S, Sproule TJ, et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 2004; 113 (9): 1328-1333
58. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialyla-tion. Science 2006; 313 (5787): 670-673
59. Anthony RM, Wermeling F, Karlsson MC, et al. Identificationofa receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105 (50): 19571-19578
60. Konrad S, Baumann U, Schmidt RE, et al. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br J Haematol 2006; 134 (3): 345-347
61. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992; 62 (1 Pt 2): S82-6
62. Mollnes TE, Hogasen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998; 48 (3): 312-317
63. Lutz HU, Stammler P, Jelezarova E, et al. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88 (1): 184-193
64. Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9 (4): 431-438
65. Rissmann A, Pieper S, Adams I, et al. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases. Pediatr Allergy Immunol 2009; 20 (3): 261-265
66. Stangel M, Schumacher HC, Ruprecht K, et al. Immuno-globulins for intravenous use inhibit TNF alpha cyto-toxicity in vitro. Immunol Invest 1997; 26 (5-7): 569-578
67. Wu KH, Wu WM, Lu MY, et al. Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatr Allergy Immunol 2006; 17 (1): 60-68
68. Ghio M, Contini P, Negrini S, et al. sHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro tran-scriptional and posttranscriptional modulation of transforming growth factor-beta in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment. Transfusion. Epub 2009 Nov 9
69. Kekow J, Reinhold D, Pap T, et al. Intravenous immuno-globulins and transforming growth factor beta. Lancet 1998; 351 (9097): 184-185
70. Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007; 26 (1): 67-78
71. Gaskin F, Finley J, Fang Q, et al. Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J Exp Med 1993; 177 (4): 1181-1186
72. Gaskin F, Kingsley BS, Fu SM. Autoantibodies to neurofibrillary tangles and brain tissue in Alzheimer's disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines. J Exp Med 1987; 165 (1): 245-250
73. Du Y, Wei X, Dodel R, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003; 126 (Pt 9): 1935-1939
74. Xu S, Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev 1997; 94 (1-3): 213-222
75. Geylis V, Kourilov V, Meiner Z, et al. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005; 26 (5): 597-606
76. Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 2006; 84 (2): 434-443
77. Schaffer C, Blanche-Ganter E. Qualitat polyvalenter Immunglobuline. Krankenhauspharmazie 1998; 19: 280-286
78. Pul R, Nguyen D, Schmitz U, et al. Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation. Clin Neuro-pharmacol 2002; 25 (5): 254-259
79. Kellner A, Matschke J, Bernreuther C, et al. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2009; 65 (1): 24-31
80. Tampellini D, Magrane J, Takahashi RH, et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 2007; 282 (26): 18895-18906
81. Moir RD, Tseitlin KA, Soscia S, et al. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 2005; 280 (17): 17458-17463
82. Song MS, Mook-Jung I, Lee HJ, et al. Serum anti-amyloidbeta antibodies and Alzheimer's disease in elderly Korean patients. J Int Med Res 2007; 35 (3): 301-306
83. Sohn JH, So JO, Hong HJ, et al. Identification of auto-antibody against beta-amyloid peptide in the serum of elderly. Front Biosci 2009; 14: 3879-3883
84. Jianping L, Zhibing Y, Wei Q, et al. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20 (3): 127-132
85. Brettschneider S, Morgenthaler NG, Teipel SJ, et al. Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol Psychiatry 2005; 57 (7): 813-816
86. Hansson SF, Andreasson U, Wall M, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 2009; 16 (2): 389-397
87. Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolec Med 2003; 3 (1): 29-39
88. Gruden MA, Davudova TB, Malisauskas M, et al. Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 18 (2): 165-171
89. Mruthinti S, Buccafusco JJ, Hill WD, et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 2004; 25 (8): 1023-1032
90. Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 2001; 49 (6): 808-810
91. Baril L, Nicolas L, Croisile B, et al. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett 2004; 355 (3): 226-230
92. Weber A, Engelmaier A, Teschner H, et al. Intravenous immunoglobulin (IVIG) Gammagard Liquid contains anti-RAGE IGG and SLRP. ICAD Abstract 2009; P3: 43
93. Dalakas MC, Spath PJ. Intravenous immunoglobulins in the third millennium. New York: Parthenon Publishing Group, 2004
94. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59 (12 Suppl. 6): S13-21
95. Quan Y, Moller T, Weinstein JR. Regulation of Fcgamma receptors and immunoglobulin G-mediated phagocytosis in mouse microglia. Neurosci Lett 2009; 464 (1): 29-33
96. Sewell WA, North ME, Cambronero R, et al. In vivo modulation of cytokine synthesis by intravenous im-munoglobulin. Clin Exp Immunol 1999; 116 (3): 509-515
97. World Health Organization. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. WHO Bulletin 1982; 60: 43-47
98. International patient organisation for primary immunodeficiencies. IVIG preparations currently available. 2009 [online]. Available from URL http://www.ipopi. org/data/ [Accessed 2010 Feb 10].
99. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006; 6 (4): 592-599
100. Martin TD. IGIV: contents, properties, and methods of industrial production-evolving closer to a more physiologic product. Int Immunopharmacol 2006; 6 (4): 517-522
101. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62 (16 Suppl. 3): S5-11
102. Relkin NR, Szabo P, Rotondi M, et al. Antibodies in the dimer fraction of IVIG have the capacity to bind beta amyloid. ICAD Abstract 2009: 43
103. Safavi A. Comparison of several human immunoglobulin products for anti-Ab 1-42 titer [abstract]. Alzheimer's Dementia 2006; 2 (3 Suppl. 1): S591
104. Balakrishnan K, Andrei-Selmer L, Selmer T, et al. Comparison of intravenous immunoglobulins for naturally occurring antibodies against b-amyloid. J Alzheimers Dis. In press
105. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6 (4): 535-542
106. Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6 (4): 257-259
107. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38 (1-3): 122-132
108. Stangel M, Kiefer R, Pette M, et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders-a prospective study. J Neurol 2003; 250 (7): 818-821
109. Brannagan 3rd TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47 (3): 674-677
110. Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50 (3): 172-175
111. Papachroni KK, Ninkina N, Papapanagiotou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007; 101 (3): 749-756
112. Shankle WR. Longitudinal measure of IVIG treatment effect in patients with Alzheimer's and Lewy body disease. ICAD Abstract 2009; P3: 43
113. Rosenmann H, Meiner Z, Geylis V, et al. Detection of circulating antibodies against tau protein in its unpho-sphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006; 410 (2): 90-93
114. Wei X, He Y, Tan J, et al. Human anti-prion protein antibodies block A117V PrProtein fibril formation and prevent A117V prion protein peptide-induced neurotoxicity. Eur Psychiatry 2008; 23: S39-S
115. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 2007; 3 (3): 120-121
116. Boulis A, Goold S, Ubel PA. Responding to the immunoglobulin shortage: a case study. J Health Polit Policy Law 2002; 27 (6): 977-99